Title : Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.

Pub. Date : 2021 Jan 28

PMID : 33507295






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Broader application of KPT-330 (selinexor), a first-in-class CRM1 inhibitor recently approved for relapsed multiple myeloma and diffuse large B-cell lymphoma, have been limited by substantial toxicity. selinexor exportin 1 Mus musculus
2 Broader application of KPT-330 (selinexor), a first-in-class CRM1 inhibitor recently approved for relapsed multiple myeloma and diffuse large B-cell lymphoma, have been limited by substantial toxicity. selinexor exportin 1 Mus musculus